Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

ACE-031 and Nandrolone Interaction: Monitor | Peptide Database

Compound Profiles ACE-031 Myostatin Inhibitor | Experimental Muscle Growth ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

ACE-031

Myostatin Inhibitor | Experimental Muscle Growth

ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling.

Nandrolone

Anabolic-Androgenic Steroid | Joint & Collagen Support

Nandrolone binds to the androgen receptor (AR) with affinity comparable to testosterone, promoting nitrogen retention, protein synthesis, and satellite cell activation in skeletal muscle tissue. Its anabolic effects are mediated through AR-dependent gene transcription that upregulates muscle-specific proteins including myosin heavy chain and IGF-1.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take ACE-031 with Nandrolone?

Yes, but with caution. Both ACE-031 and Nandrolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. Regular monitoring is advised.

Is ACE-031 and Nandrolone safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: androgenic, blood pressure raising, hpta suppressive, lipid disrupting, teratogenic. Monitor accordingly.

What are the interactions between ACE-031 and Nandrolone?

Both ACE-031 and Nandrolone suppress the HPTA axis. Combined suppression deepens shutdown and extends recovery time. Plan PCT accordingly and monitor LH/FSH/testosterone. This assessment has 46% confidence and is inferred from pharmacological mechanism analysis.

How should I time ACE-031 and Nandrolone?

ACE-031 has a half-life of 12-15 days and Nandrolone has a half-life of ~6-12 days (decanoate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

Myostatin and Cardiomyocyte Hypertrophy: Physiological vs Pathological Contexts

The distinction between physiological and pathological cardiac hypertrophy is mechanistically critical for interpreting ACE-031’s cardiac biology. Physiological hypertrophy (exercise-induce…

Source: peptideslabuk.com
Research context

Read sources and limitations before applying a claim.

Research Handling Note:

For best results in a research setting, allow both the peptide and chosen solvent to reach ambient laboratory temperature before reconstitution. This helps maintain structural integrity during dissolution. *Reconstitution solutions are supplied separately. Stock: 96 Model: ACE-031 1mg Molecular Formula: C133H227N43O33 SKU: ACE1-024 Research Only: Yes

Source: uk-peptides.com ↗

Community Research

Join others researching ACE-031 — share findings, ask questions, and learn from real experiences ACE-031 is a soluble form of the activin type IIB receptor (ActRIIB) fused to an IgG1 Fc domain. It functions as a decoy receptor, binding and neutralizing myostatin and other TGF-beta superfamily members that normally limit muscle growth. Originally developed by Acceleron Pharma for Duchenne muscular dystrophy (DMD), ACE-031 reached Phase 2 clinical trials before development was halted due to vascular side effects including nosebleeds and telangiectasia. In healthy volunteers, a single dose produced significant increases in lean mass and reductions in fat mass within 29 days. ACE-031 acts as a ligand trap for members of the TGF-beta superfamily. By mimicking the extracellular domain of the ActRIIB receptor, it intercepts myostatin (GDF-8), activin A, activin B, and GDF-11 before they can bind cell-surface receptors and activate Smad2/3 signaling. Blocking this pathway removes the natural brake on muscle protein synthesis and satellite cell proliferation, resulting in rapid skeletal muscle hypertrophy. The Fc fusion domain extends circulating half-life through FcRn-mediated recycling and provides bivalent ligand binding.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

ACE-031 Dosage, Reconstitution & Mixing Trends

See ACE-031 dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions. ACE-031 (ramatercept) is a soluble activin receptor type IIB-Fc fusion protein engineered to act as a myostatin trap, sequestering myostatin and related TGF-beta family ligands to permit muscle hypertrophy. Acceleron Pharma advanced it into Phase 2 trials in Duchenne muscular dystrophy that were halted on safety grounds. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with ACE-031. 7 ACE-031 reconstitution calculations have been logged by the WPA community. The most common dose entered is 200mcg (3 calculations). The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (5 sessions). The most common dosing frequency is once weekly (1 logged protocols). World Peptide Association aggregates anonymized peptide calculator data to show real-world dosing trends, reconstitution volumes, and vial size preferences across the research peptide community. All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.

Source: worldpeptideassociation.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides